Based on this transaction and a few others from Corporate Insiders of LQDA that Bought $1.7M worth of shares in the last 3 months, the Insider Confidence level of Liquidia Technologies is trending Up.
Since these insiders have unique insights into what's happening at Liquidia Technologies, this might serve as an indicator of where it is headed.
Here is a list of the latest insider activity for LQDA:
- Kaseta Michael - CEO,Director, Bought $47,920 worth of shares on 6 days ago
- Roger Jeffs - CFO, Bought $243,639 worth of shares on 1 week ago
- Caligan Partners LP - Director,>10% Owner,Other, Bought $1,405,000 worth of shares on 1 week ago
- Robert Lippe - COO, Bought $9,398 worth of shares on 2 weeks ago
In addition, Barchart.com has a buy rating and Yahoo! Finance has a Bullish short-term outlook.
Here is a bit more on Liquidia Technologies, LQDA but please do your own research.
LQDA Summary: Liquidia Technologies, Inc. is a late-stage clinical biopharmaceutical company. It focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. The company's product candidate consists of LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain which are in clinical stage. Liquidia Technologies, Inc. is based in NC, United States.
- Recent Last Price: $5.71
- Price Change: -$0.28, -4.67%
- Yearly Gain: 133.98%
- Market Cap: $385.53M
- P/E Ratio: -7.333
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. Click here for more on Tipranks.com.
This information was sourced from various 3rd party public sources but to get the best insight into insider activity related to LQDA, you should consider joining TipRanks.com.
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.